PF-Atlas › Clinical Trials › NCT00287716
Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Pirfenidone · Phase 3
Registry ID
NCT00287716
Phase
Phase 3
Status
Completed
Drug / intervention
Pirfenidone
Sponsor
Genentech, Inc.
Start
2006-07-14
Enrollment
435
Locations
1
About this trial
The objectives of this study are to assess the safety and efficacy of treatment with pirfenidone 2403 milligrams per day (mg/d) compared with placebo in patients with idiopathic pulmonary fibrosis (IPF), to assess the safety and efficacy of treatment with pirfenidone 1197 mg/d in patients with idiopathic pulmonary fibrosis and to characterize the pharmacokinetic disposition of pirfenidone in patients with idiopathic pulmonary fibrosis.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT00287716 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.